No Prescription |
 |
 | ||
|
SUMITREX Imigran |
|
| ||
No Prescription » Prescription Drugs 15 » SUMITREX Imigran Sumatriptan is used to treat the symptoms of migraine headaches (severe throbbing headaches that sometimes is accompanied by nausea or sensitivity to sound and light). Sumatriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels in the head and stopping pain signals from being sent to the brain. Sumatriptan does not prevent migraine attacks.Sumatriptan comes as a tablet to take by mouth and a nasal spray. It should be used at the first sign of a migraine headache. If you are at risk for heart disease and you have never taken sumatriptan before you may need to take the first dose in your doctor's office. Usually only one dose is needed. If pain is not relieved with the first dose your doctor may prescribe a second dose to be taken after at least 2 hours. Do not take more than 200 mg of the tablets or 40 mg of the nasal spray in any 24-hour period. Follow the directions on your prescription label carefully and ask your doctor or pharmacist to explain any part you do not understand. Take sumatriptan exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.Take the tablet with plenty of water or other fluids. Buy SUMITREX Imigran and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About SUMITREX Imigran: Product Type: Prescription Drugs 15 SUMITREX ( Imigran Imitrex Generic Sumatriptan ) SUMITREX (Imigran Imitrex Generic Sumatriptan) Imigran Imitrex Generic Sumatriptan 100mg Tabs Imigran Imitrex Generic Sumatriptan SUMITREX
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
